r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

JS

Jason Drew Smith

Insider · General Counsel · URGN

Jason Drew Smith files insider transactions with the SEC as a general counsel of UroGen Pharma. We hold 2 disclosed purchases and sales filed since 10 September 2020, 1 of them in the last 90 days.

  • Files forURGN
  • Disclosed buys and sells2 in all, 1 in the last 90 days
  • Last disclosure9 September 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 9 September 2020 — 8 September 2026General Counsel · UroGen Pharma 85 Form 4 lines · source: SEC Form 4

Every transaction

85 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
85 of 85 shown
8 Sep 20269 Sep 2026SEC Form 41 dsold on the open marketUroGen Pharma1,519 sharesup +2.7%up +0.0%
7 Sep 20269 Sep 2026SEC Form 42 dexercised options overnot a tradeUroGen Pharma3,334 sharesup +2.1%up +0.0%
7 Sep 20269 Sep 2026SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative3,334 sharesup +2.1%up +0.0%
3 Feb 202611 Feb 2026SEC Form 48 dsold on the open marketUroGen Pharma2,654 sharesup +125.0%up +112.9%
3 Feb 202611 Feb 2026SEC Form 48 dsold on the open marketUroGen Pharma1,608 sharesup +125.0%up +112.9%
3 Feb 202611 Feb 2026SEC Form 48 dsold on the open marketUroGen Pharma3,217 sharesup +125.0%up +112.9%
3 Feb 202611 Feb 2026SEC Form 48 dsold on the open marketUroGen Pharma2,654 sharesup +125.0%up +112.9%
3 Feb 202611 Feb 2026SEC Form 48 dsold on the open marketUroGen Pharma1,608 sharesup +125.0%up +112.9%
3 Feb 202611 Feb 2026SEC Form 48 dsold on the open marketUroGen Pharma3,217 sharesup +125.0%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharma5,500 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dwas grantednot a tradeUroGen Pharmaderivative32,609 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharma3,333 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharmaderivative5,500 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharmaderivative3,333 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharmaderivative6,667 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dwas grantednot a tradeUroGen Pharmaderivative32,609 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharma6,667 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharmaderivative5,500 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharmaderivative3,333 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharma5,500 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharma3,333 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharma6,667 sharesup +129.5%up +112.9%
31 Jan 202611 Feb 2026SEC Form 411 dexercised options overnot a tradeUroGen Pharmaderivative6,667 sharesup +129.5%up +112.9%
8 Sep 20259 Sep 2025SEC Form 41 dsold on the open marketUroGen Pharma1,520 sharesup +110.1%up +117.5%
7 Sep 20259 Sep 2025SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative3,333 sharesup +138.3%up +117.5%
7 Sep 20259 Sep 2025SEC Form 42 dexercised options overnot a tradeUroGen Pharma3,333 sharesup +138.3%up +117.5%
28 Jul 202530 Jul 2025SEC Form 42 dexercised options overnot a tradeUroGen Pharma16,500 sharesup +138.1%up +134.1%
28 Jul 202530 Jul 2025SEC Form 42 dsold on the open marketUroGen Pharma7,522 sharesup +138.1%up +134.1%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeUroGen Pharmaderivative2,500 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeUroGen Pharmaderivative6,667 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeUroGen Pharmaderivative5,500 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dwas grantednot a tradeUroGen Pharmaderivative10,000 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeUroGen Pharma2,500 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dsold on the open marketUroGen Pharma1,258 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeUroGen Pharma6,667 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dsold on the open marketUroGen Pharma3,354 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dexercised options overnot a tradeUroGen Pharma5,500 sharesup +308.7%up +298.2%
31 Jan 20254 Feb 2025SEC Form 44 dsold on the open marketUroGen Pharma2,767 sharesup +308.7%up +298.2%
9 Sep 202412 Sep 2024SEC Form 43 dexercised options overnot a tradeUroGen Pharmaderivative3,333 sharesup +237.1%up +244.8%
9 Sep 202412 Sep 2024SEC Form 43 dexercised options overnot a tradeUroGen Pharma3,333 sharesup +237.1%up +244.8%
9 Sep 202412 Sep 2024SEC Form 43 dsold on the open marketUroGen Pharma1,521 sharesup +237.1%up +244.8%
1 Feb 20245 Feb 2024SEC Form 44 dsold on the open marketUroGen Pharma417 sharesup +183.0%up +181.4%
1 Feb 20245 Feb 2024SEC Form 44 dsold on the open marketUroGen Pharma1,248 sharesup +183.0%up +181.4%
1 Feb 20245 Feb 2024SEC Form 44 dsold on the open marketUroGen Pharma3,328 sharesup +183.0%up +181.4%
31 Jan 20242 Feb 2024SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative834 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative2,500 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative6,666 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dwas grantednot a tradeUroGen Pharmaderivative16,500 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dexercised options overnot a tradeUroGen Pharma834 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dsold on the open marketUroGen Pharma417 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dexercised options overnot a tradeUroGen Pharma2,500 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dsold on the open marketUroGen Pharma1,248 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dexercised options overnot a tradeUroGen Pharma6,666 sharesup +186.6%up +173.2%
31 Jan 20242 Feb 2024SEC Form 42 dsold on the open marketUroGen Pharma3,328 sharesup +186.6%up +173.2%
7 Sep 20238 Sep 2023SEC Form 41 dwas grantednot a tradeUroGen Pharmaderivative10,000 sharesup +167.1%up +171.6%
31 Aug 20235 Sep 2023SEC Form 45 dexercised options overnot a tradeUroGen Pharmaderivative8,334 sharesup +157.4%up +150.8%
31 Aug 20235 Sep 2023SEC Form 45 dexercised options overnot a tradeUroGen Pharma8,334 sharesup +157.4%up +150.8%
31 Aug 20235 Sep 2023SEC Form 45 dsold on the open marketUroGen Pharma3,800 sharesup +157.4%up +150.8%
31 Jan 20232 Feb 2023SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative833 sharesup +333.1%up +308.3%
31 Jan 20232 Feb 2023SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative2,500 sharesup +333.1%up +308.3%
31 Jan 20232 Feb 2023SEC Form 42 dwas grantednot a tradeUroGen Pharmaderivative20,000 sharesup +333.1%up +308.3%
31 Jan 20232 Feb 2023SEC Form 42 dwas grantednot a tradeUroGen Pharmaderivative40,000 sharesup +333.1%up +308.3%
31 Jan 20232 Feb 2023SEC Form 42 dexercised options overnot a tradeUroGen Pharma833 sharesup +333.1%up +308.3%
31 Jan 20232 Feb 2023SEC Form 42 dsold on the open marketUroGen Pharma409 sharesup +333.1%up +308.3%
31 Jan 20232 Feb 2023SEC Form 42 dexercised options overnot a tradeUroGen Pharma2,500 sharesup +333.1%up +308.3%
31 Jan 20232 Feb 2023SEC Form 42 dsold on the open marketUroGen Pharma1,227 sharesup +333.1%up +308.3%
31 Aug 20222 Sep 2022SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative8,333 sharesup +504.0%up +493.7%
31 Aug 20222 Sep 2022SEC Form 42 dexercised options overnot a tradeUroGen Pharma8,333 sharesup +504.0%up +493.7%
31 Aug 20222 Sep 2022SEC Form 42 dsold on the open marketUroGen Pharma3,606 sharesup +504.0%up +493.7%
31 Jan 20222 Feb 2022SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative833 sharesup +482.9%up +511.4%
31 Jan 20222 Feb 2022SEC Form 42 dwas grantednot a tradeUroGen Pharmaderivative7,500 sharesup +482.9%up +511.4%
31 Jan 20222 Feb 2022SEC Form 42 dwas grantednot a tradeUroGen Pharmaderivative30,000 sharesup +482.9%up +511.4%
31 Jan 20222 Feb 2022SEC Form 42 dexercised options overnot a tradeUroGen Pharma833 sharesup +482.9%up +511.4%
31 Jan 20222 Feb 2022SEC Form 42 dsold on the open marketUroGen Pharma414 sharesup +482.9%up +511.4%
30 Nov 20212 Dec 2021SEC Form 42 dexercised options overnot a tradeUroGen Pharmaderivative8,333 sharesup +272.2%up +276.9%
30 Nov 20212 Dec 2021SEC Form 42 dexercised options overnot a tradeUroGen Pharma8,333 sharesup +272.2%up +276.9%
30 Nov 20212 Dec 2021SEC Form 42 dsold on the open marketUroGen Pharma3,803 sharesup +272.2%up +276.9%
5 Jun 20218 Jun 2021SEC Form 43 dwas grantednot a tradeUroGen Pharmaderivative15,000 sharesup +150.3%up +143.0%
17 May 202118 May 2021SEC Form 41 dbought on the open marketUroGen Pharma2,500 sharesup +182.0%up +155.1%
31 Jan 20212 Feb 2021SEC Form 42 dwas grantednot a tradeUroGen Pharmaderivative8,000 sharesup +103.9%up +105.2%
31 Jan 20212 Feb 2021SEC Form 42 dwas grantednot a tradeUroGen Pharmaderivative2,500 sharesup +103.9%up +105.2%
1 Oct 20205 Oct 2020SEC Form 44 dwas grantednot a tradeUroGen Pharmaderivative60,000 sharesup +128.9%up +123.0%
1 Oct 20205 Oct 2020SEC Form 44 dwas grantednot a tradeUroGen Pharmaderivative25,000 sharesup +128.9%up +123.0%
9 Sep 202010 Sep 2020SEC Form 41 dwas grantednot a tradeUroGen Pharmaderivative60,000 sharesup +110.5%up +114.3%
9 Sep 202010 Sep 2020SEC Form 41 dwas grantednot a tradeUroGen Pharmaderivative25,000 sharesup +110.5%up +114.3%

Both percentages are the stock’s move, not Jason Drew Smith’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 85 of the 85 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.